Ultime prove


EudraCT Number: 2022-003810-35 Sponsor Protocol Number: BMX-04-001 Start Date: 2023-04-25
Sponsor Name: BiomX Ltd.
Full Title: A Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate Nebulized Bacteriophage Treatment in Outpatient Adult Cystic Fibrosis (CF) Subjects with Chronic Pseudomon...
Medical condition: Cystic fibrosis Chronic Pseudomonas Aeruginosa Infection
Disease: Version SOC Term Classification Code Term Level
20.0 10010331 - Congenital, familial and genetic disorders 10011763 Cystic fibrosis lung PT
22.1 100000004862 10082869 Chronic Pseudomonas aeruginosa infection LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: ES (Ongoing) CZ (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-003408-33 Sponsor Protocol Number: ESR-21-21536 Start Date: 2023-04-25
Sponsor Name: TheraOp gGmbH
Full Title: PACCELIO - FDG-PET based small volume accelerated immuno chemoradio-therapy in locally advanced NSCLC
Medical condition: Locally advanced, unresectable non-small-cell lung cancer (NSCLC) (Stage III) with a PD-L1-expression of ≥ 1%
Disease: Version SOC Term Classification Code Term Level
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029519 Non-small cell lung cancer stage III PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-001314-19 Sponsor Protocol Number: VO659-CT01 Start Date: 2023-04-25
Sponsor Name: VICO Therapeutics B.V.
Full Title: A phase 1/2a, open-label trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of intrathecally administered VO659 in participants with sp...
Medical condition: spinocerebellar ataxia types 1, 3 and Huntington’s disease
Disease: Version SOC Term Classification Code Term Level
23.0 10010331 - Congenital, familial and genetic disorders 10057660 Spinocerebellar ataxia LLT
20.0 10010331 - Congenital, familial and genetic disorders 10070668 Huntington's disease PT
Population Age: Adults Gender: Male, Female
Trial protocol: DE (Ongoing) NL (Ongoing) IT (Ongoing) DK (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-002214-17 Sponsor Protocol Number: NL78220.029.21 Start Date: 2023-04-24
Sponsor Name: Amsterdam University Medical Centers
Full Title: COLLISION RELAPSE trial - Recurrent colorectal liver metastases: repeat local treatment +/- neoadjuvantsystemic therapy - a phase III prospective randomized controlled trial
Medical condition: Recurrent colorectal liver metastases
Disease: Version SOC Term Classification Code Term Level
21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10024700 Liver metastases LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: NL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-001413-37 Sponsor Protocol Number: BELI(E)VE-Trial Start Date: 2023-04-24
Sponsor Name: University Medical Center Hamburg-Eppendorf
Full Title: Combination treatment of Belantamab Mafodotin and Venetoclax in treatment of relapsed and refractory t(11;14) Multiple Myeloma (Phase I/IIa) The BELI(E)VE-Trial
Medical condition: relapsed and refractory t(11;14) Multiple Myeloma
Disease: Version SOC Term Classification Code Term Level
21.0 100000004864 10028228 Multiple myeloma LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-003063-10 Sponsor Protocol Number: ARGX-113-2010 Start Date: 2023-04-21
Sponsor Name: argenx BV
Full Title: An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid
Medical condition: Bullous Pemphigoid
Disease: Version SOC Term Classification Code Term Level
21.1 10040785 - Skin and subcutaneous tissue disorders 10006567 Bullous pemphigoid LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: SK (Ongoing) GR (Ongoing) HU (Ongoing) DE (Ongoing) ES (Ongoing) BG (Ongoing) IT (Ongoing) NL (Ongoing) HR (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-004155-13 Sponsor Protocol Number: BMS_IM101-931 Start Date: 2023-04-20
Sponsor Name: Universitätsklinikum Freiburg
Full Title: Study to investigate the restoring of an immunological balance during therapy with abatacept Abatacept restores immune system equilibrium (ARISE)
Medical condition: CVID patients confirmed according to ESID/PAGID criteria or related disorders which fulfill the diagnostic criteria for CVID and interstitial lung disease or granuloma diagnosed by chest CT positiv...
Disease: Version SOC Term Classification Code Term Level
20.1 10021428 - Immune system disorders 10021449 Immunodeficiency common variable PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-006664-24 Sponsor Protocol Number: INVEX-CLIN-IIH-301 Start Date: 2023-04-20
Sponsor Name: Invex Therapeutics Ltd.
Full Title: A Phase III randomised, placebo-controlled, double-blind, multi-centre, clinical trial to determine the efficacy and safety of Presendin in idiopathic intracranial hypertension
Medical condition: Idiopathic intracranial hypertension
Disease: Version SOC Term Classification Code Term Level
23.1 10029205 - Nervous system disorders 10078904 Idiopathic intracranial hypertension PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: FR (Prematurely Ended) DE (Completed)
Trial results: (No results available)
EudraCT Number: 2020-004244-28 Sponsor Protocol Number: BAN2401-G000-303 Start Date: 2023-04-17
Sponsor Name: Eisai Ltd.
Full Title: AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel Treatment Arm, 216 Week Study to Evaluate Efficacy and Safety of Treatment With BAN2401 in Subjects With Preclinical Alzheimer’s Dise...
Medical condition: Preclinical Alzheimer's Disease
Disease: Version SOC Term Classification Code Term Level
20.0 100000004852 10066571 Progression of Alzheimer's disease LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: SE (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-001175-14 Sponsor Protocol Number: BHV3000-406 Start Date: 2023-04-17
Sponsor Name: Biohaven Pharmaceuticals, Inc.
Full Title: BHV3000-406: A Phase 4, Randomized, Double-blind Placebo-Controlled, Efficacy and Tolerability Trial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use
Medical condition: migraine attacks with or without aura
Disease: Version SOC Term Classification Code Term Level
20.0 10029205 - Nervous system disorders 10027599 Migraine PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: FR (Ongoing) IT (Ongoing) SE (Ongoing) FI (Ongoing) DK (Ongoing) AT (Ongoing) ES (Ongoing)
Trial results: (No results available)
3